本报讯 "今年是封关首年，作为生物医药企业将持续创新，积极走向海外，把海南的生物医药创新成 果，通过自贸港政策'走出去'，走向全球。"省政协委员、海南苏生生物科技有限公司董事长、海南省 运动再生重点实验室主任曾胜表示，当前，海南正全力构建具有海南特色和优势的现代化产业体系，生 命健康产业迎来新的发展机遇。 "医产联动促进自贸港细胞医疗消费新增长。"曾胜希望，能设立"海口·乐城细胞治疗协同创新示范模 式"。由省发展改革委、卫健委等牵头，联动海口高新区和博鳌乐城，共建细胞治疗"研发-制备-应用-支 付"一体化模式。建立"乐城临床需求清单+海口技术供给清单"双向匹配机制，鼓励省内优质细胞研发机 构在乐城申报新技术应用，推动本地优质合规企业优先承接乐城备案新技术项目的制备任务。 曾胜提出，在已有生物医药产业政策基础上，增设细胞治疗研发及转化相关内容，对完成乐城应用的本 地企业给予奖励。探索纳入海南"惠民保"，提升可及性。突出细胞产业基金或投资方向，对生物新技术 转化提供资金助力。此外，打造面向国内外的高端医疗消费目的地。联动文旅、商务、外事等部门，推 出"细胞治疗+康养旅游"精品线路，将合规的细胞治疗项目纳入国际旅游 ...

齐鲁晚报.齐鲁壹点张晓燕通讯员翁紫宜 2025年12月，一则重磅消息为高危/复发难治性神经母细胞瘤患儿家庭带来曙光。中山大学肿瘤防治中心(简称"中肿")牵头的脐带血NK细胞治疗该病症的I 期临床试验，正式获国家卫健委批准。这是目前国内唯一获批的儿童实体瘤体细胞治疗研究项目。在这项突破的背后，是中肿与山东省齐鲁干细胞工程有 限公司(简称齐鲁干细胞)的深度协同，双方携手为研究提供核心技术支撑与优质细胞资源保障。 作为以脐带血基础研究、干细胞保存和临床应用为核心方向的高新技术企业，齐鲁干细胞的高质量发展，离不开旗下山东省脐血库的硬核支撑。作为国家 卫健委批准设立并验收合格的全国7家脐血库之一，山东省脐血库全力承担着山东省脐带血干细胞的采集、制备、储存、科研及临床输出全链条工作，不 仅是齐鲁干细胞布局细胞医疗领域的核心资源枢纽，更以高标准的资源储备与临床转化能力，为齐鲁干细胞筑牢行业领先优势。 以极致严谨守护生命之托 济南东部，一片与省地震局为邻的"净土"上，齐鲁干细胞的液氮储存罐在恒温环境中静静运转，-196℃的深低温里，100多万份细胞样本如同沉睡的生命 火种，等待着被唤醒的那一刻。这份安心，源于数十年来从未动摇 ...

Core Viewpoint - The stock of Kaineng Health reached a daily limit increase, closing at 8.48 yuan, driven by strategic moves in the cell therapy sector and strong financial performance [1][3] Group 1: Company Developments - Kaineng Health accelerated its strategic layout in the cell therapy field by establishing a subsidiary with a registered capital of 1 billion yuan, leveraging the policy advantages of Hainan's medical pilot zone to create a second growth curve [1] - The company continues to implement a high cash dividend strategy, with a projected dividend payout ratio of 67%-70% of net profit by mid-2025, enhancing market expectations regarding its cash flow [1] - The company reported steady growth in performance, with a 7.23% year-on-year increase in revenue and a 24.82% increase in net profit excluding non-recurring items for the first half of 2025, indicating improved profitability in its main business [1] Group 2: Market Performance - On November 12, 2025, Kaineng Health's stock saw a net inflow of 173 million yuan from main funds, accounting for 17.48% of total trading volume, while retail investors experienced a net outflow of 79.04 million yuan [1] - The stock is part of a broader trend, with related sectors such as stem cells, CAR-T therapy, and gene sequencing seeing respective increases of 2.96%, 1.72%, and 1.41% on the same day, indicating significant sectoral momentum [3]

Core Viewpoint - The company, Kaineng Health, is entering the cell industry by establishing a wholly-owned subsidiary, Kaineng Cell Medical Group, with an investment of 100 million yuan, aiming to create a second growth curve through this strategic move [1][2]. Group 1: Business Expansion - Kaineng Health plans to focus on the cell and biotechnology sectors, covering areas such as medical aesthetics, medical research, drug clinical trials, and cosmetics production and sales [1][2]. - The establishment of the new subsidiary is part of the company's "dual energy drive" development strategy, aimed at strengthening its position in the cell industry and expanding its business footprint [2]. Group 2: Financial Performance - In the first half of 2025, Kaineng Health reported a revenue of 889 million yuan, a year-on-year increase of 7.23%, and a net profit attributable to shareholders of 70.15 million yuan, up 22.99% [1][2]. - The company's gross profit margin reached 41.12%, an increase of 0.62 percentage points compared to the same period last year, driven by improved production efficiency [2]. Group 3: Global Strategy - Kaineng Health is actively pursuing a "going global" strategy, establishing a comprehensive ecosystem and global layout across key markets in North America, Europe, and Asia-Pacific [3]. - The company has successfully expanded its water treatment products into over 100 countries and regions, with its Canadian subsidiary, Canature N.A.Inc., achieving a net profit of 23.97 million yuan in the reporting period [3]. Group 4: Industry Potential - The global cell therapy market is projected to exceed 30 billion USD by 2025, with a compound annual growth rate of over 20%, indicating significant growth potential for the company [4]. - Kaineng Health aims to leverage its existing water treatment business and the advantages of its partner, Yuaneng Group, in the cell industry to achieve synergistic development [5].

Core Viewpoint - The company plans to establish a wholly-owned subsidiary, Kaineng Cell Medical Group Co., Ltd., in Hainan or Hunan Province with a registered capital of 100 million RMB to enhance its presence in the cell industry and pursue industry mergers and acquisitions [1] Group 1 - The subsidiary will focus on cell industry operations and related mergers and acquisitions [1] - The investment will be funded by the company's own resources, and the transaction does not require board approval, nor does it constitute a related party transaction or a major asset restructuring [1] - This initiative aims to strengthen the company's positioning in the cell industry, creating a second growth curve for the company [1]

Group 1 - The company, Zhongji Changshou Science (00767), has signed a non-binding memorandum of understanding to acquire 100% equity of the target company, Comprehensive Cell Bank Limited, from China International Orthopedic Medical Group Limited [1] - The target company specializes in cell therapy, cell drug research and development, and health longevity management services, holding the Comprehensive Cell Bank [1] Group 2 - Comprehensive Cell Bank is the largest international autologous immune cell bank in the world and is recognized for meeting various international standards, including FDA, AABB, and PIC/S cGMP [2] - The bank addresses the global challenge of insufficient international standard cell quantities and ensures safe and effective applications, positioning itself as a leading international cell transformation application platform [2] Group 3 - Since its operation began on November 17, 2018, the Comprehensive Cell Bank has developed patented technologies in cancer early screening, NK cells, stem cells, and chondrocytes, and operates 22 advanced medical testing platforms [3] - The bank can provide services to 300,000 people globally, focusing on immune cell storage, cancer early screening, longevity medical testing, and cell therapy research and development, with potential revenue exceeding HKD 30 billion [3]